🏛️ Verified NIH Record • Updated 2026-08-21

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT06124157)

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: National Cancer Institute (NCI)

🩺 Plain-English Summary (8th-Grade Level)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.

Who can join: Review the eligibility criteria below.

Location: Children's Hospital of Alabama — Birmingham, Alabama

Age range: 366 Days to 46 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (156 Sites)

Showing the first 25 of 156 sites.

  • Children's Hospital of Alabama — Birmingham, Alabama
  • Phoenix Childrens Hospital — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • Arkansas Children's Hospital — Little Rock, Arkansas
  • Kaiser Permanente Downey Medical Center — Downey, California
  • Loma Linda University Medical Center — Loma Linda, California
  • Miller Children's and Women's Hospital Long Beach — Long Beach, California
  • Children's Hospital Los Angeles — Los Angeles, California
  • Valley Children's Hospital — Madera, California
  • UCSF Benioff Children's Hospital Oakland — Oakland, California
  • Kaiser Permanente-Oakland — Oakland, California
  • Children's Hospital of Orange County — Orange, California
  • Lucile Packard Children's Hospital Stanford University — Palo Alto, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • Rady Children's Hospital - San Diego — San Diego, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
  • Children's Hospital Colorado — Aurora, Colorado
  • Connecticut Children's Medical Center — Hartford, Connecticut
  • Yale University — New Haven, Connecticut
  • Alfred I duPont Hospital for Children — Wilmington, Delaware
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • Children's National Medical Center — Washington D.C., District of Columbia
  • Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida

📞 Contact the Study Coordinator

Phone: (205) 638-9285

Email: oncologyresearch@peds.uab.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in B Acute Lymphoblastic Leukemia

Explore by condition: All B Acute Lymphoblastic Leukemia clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗